The COMBI-AD phase III trial demonstrated that patients with resected stage III BRAF-mutated melanoma who received dabrafenib and trametinib as adjuvant therapy had longer relapse-free survival (RFS) and distant metastasis-free survival compared to those receiving placebo (47). Here, BRAF is linked to melanoma.